- Dianthus Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Magenta Therapeutics Inc Definitive Merger Agreement with Dianthus Therapeutics Inc - M&A Call TranscriptMay 03, 2023
- Magenta Therapeutics Inc Update on MGTA-117 - Corporate Call TranscriptDec 13, 2022
- Magenta Therapeutics Inc at Credit Suisse Healthcare Conference TranscriptNov 08, 2022
- Magenta Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 13, 2022
- Magenta Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2021
- Magenta Therapeutics Inc MGTA-145 MM Phase 2 Clinical Trial Results Call TranscriptMay 12, 2021
- Magenta Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 14, 2021
- Magenta Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 11, 2020
- Magenta Therapeutics, Inc. - Special Call TranscriptMay 07, 2020
- Magenta Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 15, 2020
- Magenta Therapeutics Inc ASH 2019 TranscriptDec 08, 2019
- Magenta Therapeutics Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 11, 2019
Magenta Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Hey, good morning, everyone. My name is Daniel Wolle. I'm one of the analysts covering SMID-cap biotech. We're continuing the 40th Annual JPM Healthcare Conference with Magenta Therapeutics. It's my pleasure to introduce CEO and President, Jason Gardner. He will be doing presentations first, followed by Q&A. (Operator Instructions)
Without further ado, Jason?
Good morning, everyone, and thank you to JPMorgan for the opportunity to present our progress and plans at Magenta towards transforming stem cell transplant as a curative therapy for patients battling blood cancers, genetic diseases and autoimmune diseases.
Magenta is a unique clinical-stage biotech, and I'm excited to share our story, especially coming off a productive year for the portfolio in 2021. We will dive into our programs and focus on the plans for the coming year.
On the next slide is our disclosure statement
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)